Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Tekla Life Sciences Investors
Bear Case (25th pct.)
86.0% vs price
Base Case (Median)
88.2% vs price
Bull Case (75th pct.)
142.7% vs price
◇ = Current price | | Bear | Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $55.71 | 197.3% | High (40%) |
| PE Comparable | $35.27 | 88.2% | Medium (25%) |
| Graham Number | $34.42 | 83.7% | High (80%) |
Based on 3 out of 8 methods, HQL appears undervalued at the current price of $18.74. The base case fair value of $35.27 implies 88.2% upside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.